MSC Phenotyping Cocktail Kit, anti-human, REAfinity™

Name: MSC Phenotyping Cocktail Kit, anti-human, REAfinity™
Availability: InStock

MSC Phenotyping Cocktail Kit, anti-human, REAfinity™

Applications:

FC

Product data and images for MSC Phenotyping Cocktail Kit, anti-human, REAfinity™

Figures

Figure 1

Aliquot 1 of cultured MSCs was stained with the MSC Phenotyping Cocktail and aliquot 2 with the Isotype Control Cocktail. The fractions were analyzed by flow cytometry using the MACSQuant

^®

Analyzer 10. Each histogram was overlaid with the corresponding isotype control to identify positively stained cells. In order to distinguish between activated MSC and non-MSCs, the HLA-DR antibody (conjugated to different fluorochromes) has been used in combination with other MSC-negative markers.

View details MSC Phenotyping Cocktail Kit, anti-human, REAfinity™ Figure 1 Aliquot 1 of cultured MSCs was stained with the MSC Phenotyping Cocktail and aliquot 2 with the Isotype Control Cocktail. The fractions were analyzed by flow cytometry using the MACSQuant ^® Analyzer 10. Each histogram was overlaid with the corresponding isotype control to identify positively stained cells. In order to distinguish between activated MSC and non-MSCs, the HLA-DR antibody (conjugated to different fluorochromes) has been used in combination with other MSC-negative markers.	View details MSC Phenotyping Cocktail Kit, anti-human, REAfinity™ Figure 1 Aliquot 1 of cultured MSCs was stained with the MSC Phenotyping Cocktail and aliquot 2 with the Isotype Control Cocktail. The fractions were analyzed by flow cytometry using the MACSQuant ^® Analyzer 10. Each histogram was overlaid with the corresponding isotype control to identify positively stained cells. In order to distinguish between activated MSC and non-MSCs, the HLA-DR antibody (conjugated to different fluorochromes) has been used in combination with other MSC-negative markers.
View details MSC Phenotyping Cocktail Kit, anti-human, REAfinity™ Figure 1 Aliquot 1 of cultured MSCs was stained with the MSC Phenotyping Cocktail and aliquot 2 with the Isotype Control Cocktail. The fractions were analyzed by flow cytometry using the MACSQuant ^® Analyzer 10. Each histogram was overlaid with the corresponding isotype control to identify positively stained cells. In order to distinguish between activated MSC and non-MSCs, the HLA-DR antibody (conjugated to different fluorochromes) has been used in combination with other MSC-negative markers.	View details MSC Phenotyping Cocktail Kit, anti-human, REAfinity™ Figure 1 Aliquot 1 of cultured MSCs was stained with the MSC Phenotyping Cocktail and aliquot 2 with the Isotype Control Cocktail. The fractions were analyzed by flow cytometry using the MACSQuant ^® Analyzer 10. Each histogram was overlaid with the corresponding isotype control to identify positively stained cells. In order to distinguish between activated MSC and non-MSCs, the HLA-DR antibody (conjugated to different fluorochromes) has been used in combination with other MSC-negative markers.
View details MSC Phenotyping Cocktail Kit, anti-human, REAfinity™ Figure 1 Aliquot 1 of cultured MSCs was stained with the MSC Phenotyping Cocktail and aliquot 2 with the Isotype Control Cocktail. The fractions were analyzed by flow cytometry using the MACSQuant ^® Analyzer 10. Each histogram was overlaid with the corresponding isotype control to identify positively stained cells. In order to distinguish between activated MSC and non-MSCs, the HLA-DR antibody (conjugated to different fluorochromes) has been used in combination with other MSC-negative markers.	View details MSC Phenotyping Cocktail Kit, anti-human, REAfinity™ Figure 1 Aliquot 1 of cultured MSCs was stained with the MSC Phenotyping Cocktail and aliquot 2 with the Isotype Control Cocktail. The fractions were analyzed by flow cytometry using the MACSQuant ^® Analyzer 10. Each histogram was overlaid with the corresponding isotype control to identify positively stained cells. In order to distinguish between activated MSC and non-MSCs, the HLA-DR antibody (conjugated to different fluorochromes) has been used in combination with other MSC-negative markers.

Specifications for MSC Phenotyping Cocktail Kit, anti-human, REAfinity™

Overview

The MSC Phenotyping Cocktail Kit, anti-human, REAfinity enables the fast and standardized characterization and quantification of cultured human MSCs by flow cytometry based on the defined ISCT standards. The kit includes a set of ISCT proposed positive and negative markers as a ready-to-use phenotyping cocktail and also a corresponding isotype control cocktail. To ensure superior lot-to-lot consistency, low background, and high staining specificity the kit applies recombinantly engineered REAfinity antibodies.

Detailed product information

Background information

MSC Phenotyping Cocktail, anti-human, REAfinity

containing:

CD14 Antibody, anti-human, PE, REAfinity (clone: REA599)
CD19 Antibody, anti-human, PE, REAfinity (clone: REA675)
CD34 Antibody, anti-human, PE, REAfinity (clone: REA1164)
CD45 Antibody, anti-human, PE, REAfinity (clone: REA747)
CD73 Antibody, anti-human, APC, REAfinity (clone: REA804)
CD90 Antibody, anti-human, FITC, REAfinity (clone: REA897)
CD105 Antibody, anti-human, VioBlue®, REAfinity (clone: REA794)
HLA-DR Antibody, anti-human, VioGreen™, REAfinity (clone: REA805)

MSC Control Cocktail, anti-human, REAfinity containing:

REA Control Antibody (S), human IgG1, FITC, REAfinity (clone: REA293)
REA Control Antibody (S), human IgG1, PE, REAfinity (clone: REA293)
REA Control Antibody (S), human IgG1, APC, REAfinity (clone: REA293)
REA Control Antibody (S), human IgG1, VioBlue, REAfinity (clone: REA293)
REA Control Antibody (S), human IgG1, VioGreen, REAfinity (clone: REA293)

CD73 Antibody, anti-human, APC, REAfinity (clone: REA804)

CD73 Antibody, anti-human, PE, REAfinity (clone: REA804)

CD90 Antibody, anti-human, FITC, REAfinity (clone: REA897)

CD105 Antibody, anti-human, VioBlue, REAfinity (clone: REA794)

CD73 Antibody, anti-human, Biotin, REAfinity (clone: REA804)

Biotin Antibody, anti-human, VioGreen, REAfinity (clone: REA746)

Instrument details

Flow cytometer equipped with a red (640 nm), a blue (488 nm), and a violet (405 nm) laser.

Applications

Identification and phenotyping of cultured human MSCs based on the defined ISCT standards regarding marker expression analyzed by flow cytometry.

Resources for MSC Phenotyping Cocktail Kit, anti-human, REAfinity™

Documents and Protocols

Brochures/posters

MSC Phenotyping Kit, human - Confirm compliance with ISCT criteria

Brochures/posters

Workflow for human mesenchymal stem or stromal cells

Scientific posters

Clinical-scale isolation of mesenchymal stromal cells from bone marrow with the CliniMACS® System and CD271 antibody–conjugated MicroBeads

Certificates

Please follow this

link

to search for Certificates of Analysis (CoA) by lot number.

References for MSC Phenotyping Cocktail Kit, anti-human, REAfinity™

Publications

Dominici, M. et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317
Ho, Y. K. et al. (2020) A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy. Sci Rep 10: 14257
Rahman, M. S. et al. (2020)
The FGF, TGFβ and WNT axis Modulate Self-renewal of Human SIX2
⁺
Urine Derived Renal Progenitor Cells.
Sci Rep 10: 739
Sekine, K. et al. (2020) Generation of human induced pluripotent stem cell-derived liver buds with chemically defined and animal origin-free media. Sci Rep 10: 17937
Sekine, K. et al. (2020) Robust detection of undifferentiated iPSC among differentiated cells. Sci Rep 10: 10293
Kolle, S.-F. A. et al. (2020) Ex vivo‐expanded autologous adipose tissue‐derived stromal cells ensure enhanced fat graft retention in breast augmentation: A randomized controlled clinical trial. Stem Cells Transl Med 9(11): 1277-1286
Ling, J. et al. (2020) Enhancing the Efficacy of Stem Cell Therapy with Glycosaminoglycans. Stem Cell Reports 14(1): 105-121
Damerau, A. et al. (2021) A Human Osteochondral Tissue Model Mimicking Cytokine-Induced Key Features of Arthritis In Vitro. Int J Mol Sci 22(1): 128
Gaber, T. et al. (2020) Synaptotagmin-13 Is a Neuroendocrine Marker in Brain, Intestine and Pancreas. Int J Mol Sci 21(3): 865
Egger, D. et al. (2019) From 3D to 3D: isolation of mesenchymal stem/stromal cells into a three-dimensional human platelet lysate matrix. Stem Cell Res Ther. 10: 248
Chan, C. et al. (2021) Co-localisation of intra-nuclear membrane type-1 matrix metalloproteinase and hypoxia inducible factor-2α in osteosarcoma and prostate carcinoma cells. Oncol Lett. 21(2): 158
Hernández, J. J. et al. (2021) Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells. J. Transl. Med. 19: 149
Widholz, B. et al. (2019) Pooling of Patient-Derived Mesenchymal Stromal Cells Reduces Inter-Individual Confounder-Associated Variation without Negative Impact on Cell Viability, Proliferation and Osteogenic Differentiation. Cells 8(6): 633
Eremichev, R. et al. (2021) Scar-Free Healing of Endometrium: Tissue-Specific Program of Stromal Cells and Its Induction by Soluble Factors Produced After Damage. Front Cell Dev Biol. (9)
Le Naour, A. et al. (2020) Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors. J. Mol. Cell Biol. 12(3): 202
Jungbluth, P. et al. (2019) Human iPSC-derived iMSCs improve bone regeneration in mini-pigs. Bone Res. 7: 32
Gutermuth, A. et al. (2019) Descemet's Membrane Biomimetic Microtopography Differentiates Human Mesenchymal Stem Cells Into Corneal Endothelial-Like Cells. Cornea 38(1): 110

Data and images